SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?


To: Kimberly Lee who wrote (381)5/21/1998 12:12:00 PM
From: Mike McFarland  Respond to of 705
 
<"It's hard to imagine exactly why this happened," Mr. Runnels said of the stock movement.>

uh, maybe statements like this?

""We're seeing memory improvement with one dose," said Glasky, in Italy for a medical conference during which he will announce details of the trials. "There also have been behavioral improvements, care-givers are telling us. People who didn't speak who are now talking."

which I snipped from post 287,

so glad I sold most of my warrants yesterday, am about to get
stopped out of the one's I held, eeek.



To: Kimberly Lee who wrote (381)5/21/1998 1:10:00 PM
From: IMPRISTlNE  Respond to of 705
 
RE: In a physician-sponsored trial in Canada, 10 elderly patients with Alzheimer's disease were given a drug called Neotrofin. "The group showed improvement, but not each individual patient showed improvement," said Steve Runnels, the company's executive vice president

exchange2000.com

In the phase I trials, "every patient who received the drug showed more improvement than those who received the placebo," Glasky noted.

exchange2000.com